A Study of INI-822 in Healthy Volunteers and Participants With Non-alcoholic Steatohepatitis (NASH) or Presumed NASH
Status:
Recruiting
Trial end date:
2024-07-28
Target enrollment:
Participant gender:
Summary
This Phase 1 trial will explore the safety, tolerability, pharmacokinetics (PK) and
pharmacodynamics (PD) of single and multiple ascending doses of INI-822 in healthy volunteers
in Parts A and B and in participants with a history of NASH or presumed NASH in Part C.